Investigation Into the Natural History and Metabolic and Molecular Basis of RASopathies.

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The RASopathies are a group of developmental disorders caused by genetic changes in the genes that compose the Ras/mitogen activated protein kinase (MAPK) pathway. New RASopathies are being diagnosed frequently. This pathway is essential in the regulation of the cell cycle and the determination of cell function. Thus, appropriate function of this pathway is critical to normal development. Each syndrome in this group of disorders has unique phenotypic features, but there are many overlapping features including facial features, heart defects, cutaneous abnormalities, cognitive delays, and a predisposition to malignancies. This research study proposes to collect and store human bio-specimens from patients with suspected or diagnosed RASopathies. Once obtained, blood and/or tissue samples will be processed for: metabolic function studies, biomarkers, genetic studies, and/or the establishment of immortalized cell lines. In addition, data from the medical record (including neuropsychological evaluations) and surveys will be stored to create a longitudinal database for research conducted at CCHMC or at other research institutions.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: t
View:

• Patients with a suspected or known diagnosis of any of the group of disorders known as RASopathies (e.g., Neurofibromatosis, Costello Syndrome, Noonan Syndrome). Diagnosis may be made clinically and/or confirmed through genetic testing.

• Unaffected relatives of patients with a suspected or known diagnosis of any of the group of disorders known as RASopathies.

Locations
United States
Ohio
Cincinnati Children's Hospital Medical Center
RECRUITING
Cincinnati
Contact Information
Primary
Lindsey Aschbacher-Smith, MS
Lindsey.Aschbacher-Smith@cchmc.org
513-803-0077
Backup
Laurie Bailey, MS
Laurie.Bailey@cchmc.org
513-636-4507
Time Frame
Start Date: 2017-06-27
Estimated Completion Date: 2065-12
Participants
Target number of participants: 1000
Treatments
Neurofibromatosis 1 (NF1)
Individuals with a confirmed or suspected diagnosis of Neurofibromatosis Type 1 (NF1). Diagnosis may be made clinically and/or confirmed through genetic testing. Clinical (non-genetic) diagnosis requires that individuals meet the National Institute of Health's (NIH) clinical diagnostic criteria for NF1.
Noonan Syndrome
Individuals with a confirmed or suspected diagnosis of Noonan Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
Noonan Syndrome with Multiple Lentigines
Individuals with a confirmed or suspected diagnosis of Noonan Syndrome with Multiple Lentigines. Diagnosis may be made clinically and/or confirmed through genetic testing.
Noonan Neurofibromatosis Syndrome
Individuals with a confirmed or suspected diagnosis of Noonan Neurofibromatosis Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
Cardiofaciocutaneous Syndrome
Individuals with a confirmed or suspected diagnosis of Cardiofaciocutaneous Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
Costello Syndrome
Individuals with a confirmed or suspected diagnosis of Costello Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
Legius Syndrome
Individuals with a confirmed or suspected diagnosis of Legius Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
Smith-Kingsmore Syndrome
Individuals with a confirmed or suspected diagnosis of Smith-Kingsmore Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
GATOR-1 Mutation
Individuals with a suspected or known mutation of GATOR-1.
SYNGAP1-Related Intellectual Disability
Individuals with a suspected or known mutation of SYNGAP1.
DLG4 Mutation
Individuals with a suspected or known mutation of DLG4.
MAPK1 Gene Mutation
Individuals with a suspected or known mutation of MAPK1.
MTOR Gene Mutation
1. Individuals with a suspected or known mutation of a gene associated with the MTOR cellular pathway. Diagnosis may be made clinically and/or confirmed through genetic testing.~2. Unaffected relatives of individuals with a suspected or known mutation of a gene associated with the MTOR cellular pathway.
RAS Mutation
1. Individuals with a suspected or known mutation of a gene associated with the RAS/MAPK cellular pathway. Diagnosis may be made clinically and/or confirmed through genetic testing.~2. Unaffected relatives of individuals with a suspected or known mutation of a gene associated with the RAS/MAPK cellular pathway.
Sponsors
Leads: Children's Hospital Medical Center, Cincinnati

This content was sourced from clinicaltrials.gov